{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:00:22Z","timestamp":1792414822208,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Nordic Cancer Union","award":["D-03-\/08"],"award-info":[{"award-number":["D-03-\/08"]}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1093\/annonc\/mds621","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T20:46:41Z","timestamp":1355777201000},"page":"1385-1392","source":"Crossref","is-referenced-by-count":102,"title":["Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study"],"prefix":"10.1016","volume":"24","author":[{"given":"H.","family":"Holte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8.","family":"Fluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jyrkki\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Delabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Erlanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Foss\u00e5","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"\u00d8stenstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"L\u00f6fvenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds621_bb0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factor Project: a predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds621_bb0015","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"A phase III comparison of CHOP versus m-BACOD versus ProMACE-CytaBOM versus MACOP-B in patients with intermediate or high grade non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds621_bb0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds621_bb0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) group","volume":"7","author":"Pfreundshuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds621_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0035","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0040","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"20","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0045","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0050","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds621_bb0060","first-page":"1304","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis","volume":"88","author":"Strehl","year":"2003","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds621_bb0065","first-page":"CD004024","article-title":"High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults","author":"Greb","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mds621_bb0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.critrevonc.2011.04.010","article-title":"Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer","volume":"81","author":"Lymana","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mds621_bb0075","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1008260120532","article-title":"For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?","volume":"9","author":"Bos","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0085","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/annonc\/mdm073","article-title":"Central nervous system occurrence in elderly patients with aggressive non-Hodgkin lymphoma and a long term follow-up","volume":"18","author":"Bj\u00f6rkholm","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0095","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma","volume":"19","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0105","series-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mds621_bb0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008394827806","article-title":"Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients","volume":"11","author":"Haioun","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0120","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomized phase II trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds621_bb0125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8002","volume":"29","author":"Schmitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdr058","article-title":"R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R- CHOP-14. A population-based investigation from the Danish Lymphoma Group","volume":"23","author":"Gang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1996.14.2.399","article-title":"Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia","volume":"14","author":"Relling","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0145","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the South Westy Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0150","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cncr.26588","article-title":"Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds621_bb0155","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","article-title":"Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab","volume":"90","author":"Tai","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mds621_bb0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2010.01438.x","article-title":"Central nervous system involvement in diffuse large B-cell lymphoma","volume":"85","author":"Yamamoto","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mds621_bb0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.blre.2011.12.001","article-title":"CNS prophylaxis in diffuse large B-cell lymphoma. If, when, how and for whom?","volume":"26","author":"Siegal","year":"2012","journal-title":"Blood Rev"},{"key":"10.1093\/annonc\/mds621_bb0175","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds621_bb0180","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/annonc\/mdl434","article-title":"The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma","volume":"18","author":"Arkenau","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds621_bb0190","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0195","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0200","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2006.05.5897","article-title":"Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma","volume":"24","author":"van Imhoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds621_bb0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000324206","article-title":"High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab","volume":"126","author":"Gaudio","year":"2011","journal-title":"Acta Haematol"},{"key":"10.1093\/annonc\/mds621_bb0210","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0215","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","article-title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"109","author":"Nyman","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds621_bb0220","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"A gene expression-based survival predictor for diffuse large B cell lymphoma treated with chemotherapy plus rituximab","volume":"359","author":"Lenz","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds621_bb0225","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds621_bb0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419372424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/5\/1385\/570863\/mds621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:32:23Z","timestamp":1714725143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419372424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0923753419372424"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds621","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969640.793469208","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}